GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Tianyu Pharmaceutical Co Ltd (SZSE:300702) » Definitions » Total Assets

Zhejiang Tianyu Pharmaceutical Co (SZSE:300702) Total Assets : ¥6,489 Mil (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Zhejiang Tianyu Pharmaceutical Co Total Assets?

Zhejiang Tianyu Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2025 was ¥6,489 Mil.

During the past 12 months, Zhejiang Tianyu Pharmaceutical Co's average Total Assets Growth Rate was 2.10% per year. During the past 3 years, the average Total Assets Growth Rate was 4.50% per year. During the past 5 years, the average Total Assets Growth Rate was 17.40% per year. During the past 10 years, the average Total Assets Growth Rate was 22.60% per year.

During the past 12 years, Zhejiang Tianyu Pharmaceutical Co's highest 3-Year average Total Assets Growth Rate was 32.00%. The lowest was 4.50%. And the median was 24.00%.

Total Assets is connected with ROA %. Zhejiang Tianyu Pharmaceutical Co's annualized ROA % for the quarter that ended in Mar. 2025 was 5.28%. Total Assets is also linked to Revenue through Asset Turnover. Zhejiang Tianyu Pharmaceutical Co's Asset Turnover for the quarter that ended in Mar. 2025 was 0.12.


Zhejiang Tianyu Pharmaceutical Co Total Assets Historical Data

The historical data trend for Zhejiang Tianyu Pharmaceutical Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Tianyu Pharmaceutical Co Total Assets Chart

Zhejiang Tianyu Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,904.17 5,800.60 6,415.75 6,338.12 6,578.58

Zhejiang Tianyu Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,174.54 6,266.82 6,429.93 6,578.58 6,488.59

Zhejiang Tianyu Pharmaceutical Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Zhejiang Tianyu Pharmaceutical Co's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=3497.774+3080.802
=6,579

Zhejiang Tianyu Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2025 is calculated as

Total Assets=Total Equity (Q: Mar. 2025 )+Total Liabilities (Q: Mar. 2025 )
=3586.119+2902.474
=6,489

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Tianyu Pharmaceutical Co  (SZSE:300702) Total Assets Explanation

Total Assets is connected with ROA %.

Zhejiang Tianyu Pharmaceutical Co's annualized ROA % for the quarter that ended in Mar. 2025 is

ROA %=Net Income (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=344.732/( (6578.576+6488.593)/ 2 )
=344.732/6533.5845
=5.28 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Zhejiang Tianyu Pharmaceutical Co's Asset Turnover for the quarter that ended in Mar. 2025 is

Asset Turnover
=Revenue (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=759.324/( (6578.576+6488.593)/ 2 )
=759.324/6533.5845
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Zhejiang Tianyu Pharmaceutical Co Total Assets Related Terms

Thank you for viewing the detailed overview of Zhejiang Tianyu Pharmaceutical Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Tianyu Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Chemical Development Zone, Zhejiang Province, Huangyan, Jiangkou, Taizhou, CHN, 318020
Zhejiang Tianyu Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. Its main business is the development, production and sales of active pharmaceutical ingredients and intermediates. The products mainly include antihypertensive drug and intermediates, anti-asthma drug raw materials and intermediates, antiviral drug intermediates. Its products are well sold in domestic and overseas markets.
Executives
Cheng Rong De Directors, executives
Wang Yan Directors, executives
Lin Jie Director
Li Gong Yong Executives
Yang Xiao Song Executives
Fang Hong Jun Directors, executives
Zhu Guo Rong Executives
Zhang Yi Executives
Zhang Jia Liu Executives
Li Mei Jun Executives
Jiang Lu Lu Securities Affairs Representative
Tu Yong Jun Directors, executives

Zhejiang Tianyu Pharmaceutical Co Headlines

No Headlines